Leveraging 18+ Years of Academic Research

Translating long-term scientific work into clinically actionable diagnostic innovations.

Proprietary Prognostic Algorithm

Proprietary Prognostic Algorithm

A proprietary algorithm designed to improve precision in prostate cancer prognosis.

Tissue-Based Immunoassay

Tissue-Based Immunoassay

A tissue-based immunoassay developed to predict therapy response across multiple solid tumors including breast, colon, prostate, and glioblastoma.

Companion Diagnostic Testing

Companion Diagnostic Testing

Tissue-based and blood-based immunoassays developed as companion diagnostic tests for multiple solid tumors.

Richard Pestell

AO., MD., PhD, MBA, Founder & CEO

Globally recognized oncology leader and translational research innovator.

Richard Pestell

Leadership & Institutional Roles

  • Relevant start-up experience / Founded & Funded ProstaGene, Lightseed & EcoGenome

  • Director Lombardi Comprehensive Cancer Center

  • Director Sidney Kimmel Comprehensive Cancer Center

  • Chairman, Department of Oncology

Research & Scientific Impact

  • 600 papers, >110,000 citations, H-index 162

  • Google Scholar rankings (#1 cell cycle, #5 Prostate, #13 Breast)

  • World Ranked Oncology Research

Innovation & Patents

  • Inventor of 30 Patents

  • Relevant start-up experience

  • Established Phase 1 program

Clinical & Advisory Experience

  • Oversaw >120 clinical trials (Phases 1, 2, & 3)

  • Current examiner of NCI designated centers

  • Advisor | Reviewer for NCI | MD Anderson

Richard Pestell

The StromaGenesis Team

András Benczúr, PhD

András Benczúr, PhD

CAIO

  • Andreas received his Ph.D at the Massachusetts Institute of Technology (MIT) in 1997

  • His interest turned to Information Retrieval and Web Search

  • He was representing SZTAKI as Principal Investigator in several EU and National R&D projects

  • He received a major permanent grant of the President of the Hungarian Academy of Sciences for Big Data Research in 2012

Dr. Xiaoming Jiao

Dr. Xiaoming Jiao

CSO

  • Associate Professor at the Baruch S. Blumberg Institute

  • Instructor in Cancer Biology at Sidney Kimmel Cancer Center, Thomas Jefferson University, from 2005-2016

  • Jiao studies CCR5 antagonists, tumor suppressors, & oncogenes to block tumor metastasis and stem cell growth.

Stephen Hull

Stephen Hull

Reimbursement Consultant

  • Principal at Covance

  • Senior Vice President for Global Reimbursement at AdvaMed

  • President & Founder of Hull Associates LLC (global reimbursement strategy firm focused on pharmaceutical, medical device, diagnostic & biotech technologies) (Boston, MA) now Avania

Dr. Alberto Guitirez

Dr. Alberto Guitirez

Regulatory Consultant

  • Director of the FDA’s Office of In Vitro Diagnostics and Radiological Health from 2009-2017

  • Gutierrez guides regulatory strategy, device approvals, and compliance for in vitro diagnostics and radiological devices, advising biopharma and medical device clients through NDA Partners.

Kevin Ellison

Kevin Ellison

Consultant

  • Head of Business Development for North America at Almac Diagnostic Services

  • Ellison supports biomarker discovery and companion diagnostics, builds key partnerships, and guides biopharma teams in using diagnostic solutions, assay design, & lab data across global clinical programs.

Dr. Hallgeir Rui MD, PhD

Dr. Hallgeir Rui MD, PhD

Consultant

  • Professor of Pharmacology, Physiology and Cancer Biology Thomas Jefferson University

  • Director of the Pathology Translational Research Shared Resource at Sidney Kimmel Comprehensive Cancer Center

  • Rui leads a lab in molecular profiling and resistance in HR-positive breast cancer

Andrew Kossenkov, PhD

Andrew Kossenkov, PhD

Bioinformatics Consultant

  • Assistant Professor at the Vaccine & Immunotherapy Center

  • Kossenkov applies computational approaches to biomedical high-throughput data analysis, interpreting results and visualizing complex data, following his training in computer science, bioinformatics & biomedical science at multiple institutes in Philadelphia.

Professor Z. Li

Professor Z. Li

Consultant

  • Associate Professor at the Baruch S. Blumberg Institute

  • Li researches tumor development in breast & prostate cancer, including DACH1 regulation, DNA repair, cyclin D1, & BCL6 pathways, & her work informs molecular mechanisms & therapy strategies in cancer research.

StromaGenesis Advisory Board

Dr. Fernando Rubio, PhD

Dr. Fernando Rubio, PhD

Chief Executive Officer, Eurofins Abraxis L.L.C.

Founder Abraxis, Clinical diagnostics (genetics), manufacturing and distribution company. >110 million tests per year.

Eurofins clinical diagnostics laboratories offer testing services in all medical specialties, from routine testing to esoteric testing including advanced and often proprietary genetic testing solutions. (now Gold Standards Diagnostic)

Dr. Thomas Errico, MD

Dr. Thomas Errico, MD

Board-certified orthopedic surgeon since 1986 & pediatric spine surgeon at Nicklaus Children’s Hospital

Founder of K2M Group Holdings, Inc. Co-Founder of Electrocore and SpineCore Chief of Spine Surgery at NYU Langone from 1998-2018 Errico specializes in spinal surgery.

Dr. Denis Burger, PhD

Dr. Denis Burger, PhD

Developed and brought 4 companies to NASDAQ

Trinity Biotech Co-founder and Chairman Previous Vice Chairman of CytoDyn Inc. Chairman and Chief Executive Officer of AVI Biopharma Inc, non-executive director of Aptose Biosciences, Inc, a cancer therapeutics, TSX and NASDAQ listed company, and co-founder and Chairman of Epitope Inc

Dr. Hallgeir Rui, MD, PhD

Dr. Hallgeir Rui, MD, PhD

Professor of Pharmacology & Cancer Biology, Thomas Jefferson University

Director, Translational Pathology Core, Sidney Kimmel Cancer Center